
Boston Scientific's $9 million insider buy is a vote against the WATCHMAN panic
Three insiders bought $9.29 million of BSX shares in roughly two weeks, including a roughly $9 million purchase by CEO Michael Mahoney. That confidence signal lands alongside 19.9% revenue growth, 55.6% EPS growth and a valuation that already reflects a reset.










